Author:
Fernández-Santander Ana,Gaibar María,Novillo Apolonia,Romero-Lorca Alicia,Rubio Margarita,Chicharro Luis Miguel,Tejerina Armando,Bandrés Fernando
Publisher
Public Library of Science (PLoS)
Reference49 articles.
1. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors;B Fisher;J Natl Cancer Ins,1996
2. Pharmacological characterization of 4-hydroxy- N-desmethyl tamoxifen, a novel active metabolite of tamoxifen;MD Johnson;Breast Cancer Res Treat,2004
3. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, et al.. (2005) Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. 28th Annual San Antonio Breast Cancer Symposium Dec 08–11; San Antonio, TX.
4. Pharmacogenetics in Breast Cancer Therapy;SH Tan;Clin Cancer Res,2008
5. Very important pharmacogene summary: sulfotransferase 1A1;M Hildebrandt;Pharmacogenet Genomics,2009
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献